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Abstract: To assess pulmonary vascular metrics on chest CT of COVID-19 patients, and their correlation 
with pneumonia extent (PnE) and outcome, we analyzed COVID-19 patients with an available previous chest 
CT, excluding those performed for cardiovascular disease. From February 21 to March 21, 2020, of 672 
suspected COVID-19 patients from two centers who underwent CT, 45 RT-PCR-positives (28 males, median 
age 75, IQR 66–81 years) with previous CTs performed a median 36 months before (IQR 12–72 months)  
were included. We assessed PnE, pulmonary artery (PA) diameter, ascending aorta (Ao) diameter, and PA/
Ao ratio. Most common presentations were fever and dyspnea (15/45) and fever alone (13/45). Outcome 
was available for 41/45 patients, 15/41 dead and 26/41 discharged. Ground-glass opacities (GGOs) alone 
were found in 29/45 patients, GGOs with consolidations in 15/45, consolidations alone in 1/45. All but 
one patient had bilateral pneumonia, 9/45 minimal, 22/45 mild, 9/45 moderate, and 5/45 severe PnE. PA 
diameter (median 31 mm, IQR 28–33 mm) was larger than before (26 mm, IQR 25–29 mm) (P<0.001), PA/
Ao ratio (median 0.83, IQR 0.76–0.92) was higher than before (0.76, IQR 0.72–0.82) (P<0.001). Patients 
with adverse outcome (death) had higher PA diameter (P=0.001), compared to discharged ones. Only weak 
correlations were found between ΔPA or ΔPA/Ao and PnE (ρ≤0.453, P≤0.032), with 4/45 cases with moderate-
severe PnE and minimal increase in PA metrics. In conclusion, enlarged PA diameter was associated to death 
in COVID-19 patients, a finding deserving further investigation as a potential driver of therapy decision-
making.
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Introduction
Pathophysiological lung changes in patients affected by 
the novel Coronavirus Disease (COVID-19) are easily 
detectable with computed tomography (CT) and mirror the 
possible evolution from viral pneumonia to acute respiratory 
distress syndrome (ARDS) (1-7). Bilateral interstitial 
abnormalities are initially present as subpleural ground-
glass opacities (GGOs), while progressive consolidations 
and reticular patterns can lately appear, reaching a large 
extent if cytokine dysregulation induces ARDS with diffuse 
alveolar and interstitial damage (1,3,5).
Extensive lung consolidation and ARDS can alter 
pulmonary vasculature features (8), engendering pulmonary 
hypertension (9,10), which in COVID-19 patients could 
also be caused by an overlap of these processes with 
increasingly-reported pulmonary arterial thrombosis (11-
15). Early detection of pulmonary hypertension is therefore 
paramount to guide appropriate treatment (8) but remains 
a complex diagnostic challenge, also hampered by different 
and complementary shortcomings of available diagnostic 
techniques (10,16). While COVID-19 patients frequently 
undergo unenhanced CT, administration of iodinated contrast 
agents for CT pulmonary angiography, which would facilitate 
the diagnosis of pulmonary arterial thrombosis, may be 
contraindicated in COVID-19 patients. However, unenhanced 
CT measurements of the ratio between maximum diameters 
of the pulmonary artery (PA) and the ascending aorta (Ao)—
PA/Ao ratio—were found to represent a helpful non-invasive 
option to detect pulmonary hypertension (9,10,16,17). A cut-
off value of 29 mm for PA diameter is generally accepted 
as highly suggestive of pulmonary hypertension (16,18), 
while a PA/Ao ratio >0.9 has been found to be progressively 
correlated with pulmonary vascular impairment (9,10,17).
This retrospective study, performed in two hospitals near 
to the first area put in quarantine during the COVID-19 
pandemic in Italy, aimed to evaluate intra-individual 
variations of pulmonary vascular metrics in COVID-19 
patients, comparing unenhanced CT scans performed 
after emergency room (ER) admission and previous CTs 
performed for any reason except cardiovascular disease 
assessment, and to correlate vascular metrics to pneumonia 
extent (PnE) and clinical outcomes.
Methods
Study population
The local Ethics Committees approved this retrospective 
study (Ethics Committee of Brescia; protocol code NP 
4154; approved on May 13, 2020).
COVID-19 patients who underwent thoracic CT at ASST 
Crema - Ospedale Maggiore, Crema, Italy; Center 1 and 
Fondazione Poliambulanza Istituto Ospedaliero, Brescia, 
Italy; Center 2 after ER admission from February 21 to March 
21, 2020, were identified. At both institutions, during this 
timeframe, waiting times for reverse transcriptase-polymerase 
chain reaction (RT-PCR) results were too high to correctly 
triage the sheer number of suspected COVID-19 patients, CT 
being temporarily performed as a triaging test. We included 
in this study only patients who had subsequent confirmation 
of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection by RT-PCR and had already performed 
another thoracic CT at the same institution for other clinical 
queries (except for cardiovascular disease): these previous CTs 
were considered as baseline examinations. Outcome data and 
arterial partial pressure of oxygen at admission (PaO2-Adm) 
were retrieved from clinical records.
Image acquisition
At Center 1, all examinations during the COVID-19 
pandemic were performed on one of the two currently-
installed 64×2-slices CT scanners (Aquilion CXL, 
Toshiba/Canon Medical Systems, Ōtawara, Japan, or 
Revolution EVO, General Electric Healthcare, Chalfont 
St. Giles, UK), while all baseline examinations had been 
performed on the formerly-installed 16-slices CT scanner 
(Diamond Select Brilliance 16, Philips Healthcare, Best, 
The Netherlands). At Center 2, all current and baseline 
examinations were performed on a 16-slices CT scanner 
(LightSpeed RT 16, General Electric Healthcare, Chalfont 
St. Giles, UK). Patients’ conditions were monitored during 
the procedure and all current scans were performed without 
the administration of iodinated contrast agents. 
Image analysis
Two dedicated radiologists, with 7- and 20-year experience 
from each center, reviewed CTs from their own institution 
to assess pulmonary parenchyma, pulmonary vascular 
metrics, and Ao maximum diameter.
Lung parenchyma was assessed for the presence of the 
following features: GGOs and/or consolidation, crazy-paving 
pattern, pleural effusion, mediastinum lymphadenopathy. PnE 
was visually assessed according to the categories proposed by 
Bernheim et al. (2): 0% (absent); 1–25% (minimal); 26–50% 
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(mild); 51–75% (moderate); over 75% (severe). 
Perilesional vascular enlargement, defined as presence/
absence of enlargement of pulmonary vessels next to lung 
parenchymal opacities, was qualitatively assessed (4).
Finally, as described by Wells et al. (9), the PA maximum 
diameter at the level of its bifurcation and the Ao maximum 
diameter were assessed in a single slice (Figure 1), and PA/
Ao ratio then calculated. 
Statistical analysis
Data were reported as mean and standard deviation (SD) 
or as median and IQR according to their normal or non-
normal distribution, assessed with the Shapiro-Wilk test. 
The Wilcoxon test was used to assess significant differences 
among PA/Ao ratio and PA maximum diameter before and 
after SARS-CoV-2 infection, Spearman’s ρ being used to 
assess correlations between vascular metrics, PnE, admission 
PaO2, and hospitalization length. The Mann-Whitney U 
test and the χ2 test were used to compare vascular metrics 
and PnE between groups with different outcomes.
Statistical analysis was performed using SPSS v.22.0 (IBM 
SPSS Inc., Chicago, IL, USA), and P values <0.05 were 
considered statistically significant.
Results
Population characteristics
In the study timeframe, 374 patients underwent triage 
chest CT for suspected SARS-CoV-2 infection at Center 
1, 298 patients at Center 2. A previous CT examination 
was available for 45 of subsequently confirmed COVID-19 
patients (median age 75.2 years, IQR 66.0–81.0 years), 
twenty-eight of them (62%) being males. At ER admission, 
fifteen patients (33%) had both fever and dyspnea, nine 
(20%) patients had both fever and cough, thirteen (29%) 
only fever, four (9%) only dyspnea, one (2%) only cough, 
and three (7%) respiratory insufficiency. PaO2-Adm was 
available for 37 patients, with a median 70 mmHg (IQR 
55–94 mmHg). Outcome data were available for 41/45 
patients, 15/41 (37%) died after progression to severe 
ARDS and 26/41 (63%) discharged after a median 10 days 
hospitalization (IQR 0–20 days).
The previous CT scans used as baseline examinations 
were performed a median 36 months before ER admission 
(IQR 12–72 months).
Pulmonary parenchymal CT features
All but one patient had bilateral pneumonia, GGOs without 
consolidation being found in 29 (65%) patients, both GGOs 
and consolidation in 15 (33%), consolidations alone in one 
patient only (2%). Only one patient had associated crazy-
paving. PnE was categorized as minimal in nine patients 
(20%), mild in 22 (49%), moderate in 9 (20%), and severe 
in 5 (11%). Pulmonary perilesional vascular enlargement 
was found in 10 patients (22%), 6 of them with bilateral 
consolidations. Five patients had bilateral pleural effusion 
Figure 1 Pulmonary artery to ascending aorta (PA/Ao) ratio assessed on axial contrast-enhanced CT at baseline (A) and unenhanced at 
emergency room admission for suspected SARS-CoV-2 infection (B) in a 51-year-old woman with confirmed SARS-CoV-2 infection. 
Baseline CT was performed the previous year for oncologic follow-up. Soon after SARS-CoV-2 infection was confirmed, the patient began 
to show bilateral ground glass opacities and consolidation, with mild pneumonia extent. 
BA
21 mm
33 mm
35 mm
26 mm
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and three others showed mediastinum lymphadenopathies.
Vascular metrics
Median PApre diameter was 26 mm (IQR 25–29 mm), median 
PApost diameter was 31 mm (IQR 28–33 mm) (P<0.001, Figures 
1,2), and median overall ΔPApost-pre was 3 mm (IQR 1–5 mm). 
Median Aopre diameter was 35 mm (33–39 mm), while median 
Aopost diameter was 36 mm (IQR 33–39 mm) (P=0.005).
Median PA/Ao ratio at ER admission (0.83, IQR 0.76–
0.92) was significantly higher (P<0.001) than at baseline 
(0.76, IQR 0.72–0.82), the median overall value of ΔPA/
Aopost-pre being 0.07 (IQR 0.02–0.11).
Correlation between clinical data, radiological data, and 
outcome
In patients with unfavorable outcome (i.e., death), we found 
lower PaO2-Adm values (U=77, P=0.023) and worse PnE 
(P=0.024) than in discharged patients. Among vascular 
metrics, only the PApost diameter was significantly higher 
(U=74, P=0.001) in patients with unfavorable outcome. 
As noticeable in Figure 3, ΔPApost-pre values showed 
a significant but weak correlation with PnE (ρ=0.321, 
P=0.032). ΔPA/Aopost-pre values (Figure 4) showed a higher 
correlation with PnE (ρ=0.453, P=0.002), and a relatively 
higher correlation was also found between PA/Ao ratio 
at ER admission and PnE (ρ=0.631, P<0.001) (Figure 5). 
PaO2-Adm values likewise showed a significant but 
intermediate correlation with PnE (ρ=–0.459, P=0.004) 
and a significant but weak correlation with PA/Ao ratio at 
ER admission (ρ=–0.356, P=0.030). No other correlation 
was found among vascular metrics and the duration of 
hospitalization before discharge or death. 
Discussion
Known disruption of pulmonary hemodynamics following 
Figure 2 Axial unenhanced CT images at baseline (A) and at emergency room admission for suspected SARS-CoV-2 infection (B) in a 
66-year-old man with confirmed COVID-19. Baseline CT was performed the previous year for oncologic follow-up. In (B), the patient had 
bilateral ground glass opacities with severe pneumonia extent and enlarged pulmonary artery.
BA
26 mm
31 mm
Figure 3 ΔPApost-pre values and their relations with the four 
categories of pneumonia extent. A, minimal pneumonia extent; B, 
mild pneumonia extent; C, moderate pneumonia extent; D, severe 
pneumonia extent.
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Figure 4 ΔPA/Aopost-pre values and their relations with the four 
categories of pneumonia extent. A, minimal pneumonia extent; B, 
mild pneumonia extent; C, moderate pneumonia extent; D, severe 
pneumonia extent.
Figure 5 PA/Aopost values and their relations with the four 
categories of pneumonia extent. A, minimal pneumonia extent; B, 
mild pneumonia extent; C, moderate pneumonia extent; D, severe 
pneumonia extent.
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large scale consolidation with inflammatory and vascular 
changes, expressed as vascular enlargement (4), could also 
be a concern in COVID-19 patients, which already present 
a frail intravascular equilibrium with high thromboembolic 
risk (15,19-25). Diagnosis of pulmonary hypertension 
is fraught with complications (8-10,16,17), but CT 
measurements of PA diameter and PA/Ao ratio constitute a 
helpful non-invasive option for the detection of pulmonary 
hypertension even in unenhanced CT, as demonstrated 
on large populations (9,17). While such metrics are easily 
attainable in COVID-19 patients which already perform 
unenhanced CT scans and could represent a potential 
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prognostic index, to date no study to evaluate possible 
pulmonary hypertension has been conducted on these 
patients. We therefore performed this retrospective study 
considering two of the first clusters of patients in the Italian 
COVID-19 epidemic, aiming to compare intra-patient 
vascular metrics on chest CT performed before and during 
SARS-CoV-2 infection and their correlation with baseline 
PaO2 and patient outcome. Including only patients with a 
previous CT, our data comes from fragile patients, with a 
median age of 75 years and main reason to perform previous 
examinations of oncological nature. 
When measuring PA diameter after SARS-CoV-2 
infection we found a median value of 31 mm (IQR 28–33 
mm), above the 27 mm and 29 mm reference values 
established for women and men, respectively, in the 
Framingham Heart Study (18). The large majority (37/45, 
82%) of COVID-19 patients from our cohort presented 
an increased PA caliper compared to their baseline 
measurements. We also found an increase both in the median 
PA/Ao ratio and in the PA diameter absolute median value, 
that rose from 26 to 31 mm after SARS-CoV-2 infection. 
Of note, all ten patients without an increased PA/Ao ratio 
showed already high baseline values for both components 
of this parameter, suggesting that an increase in pulmonary 
vascular pression may be related to the inflammatory status 
triggered by SARS-CoV-2 infection. 
While an intermediate correlation was found between 
PaO2-Adm and PnE, we found a weak correlation both 
between PaO2-Adm and PA/Aopost and between vascular 
metrics and PnE, as depicted in Figures 6,7. Considering 
the two categories with lowest PnE, we observed 9 patients 
with ΔPApost-pre values higher than the overall median value 
(Figure 6), and 11 patients with ΔPA/Aopost-pre higher than 
the overall median value (Figure 7). Conversely, considering 
the two categories with highest PnE, we observed 4 patients 
with ΔPApost-pre values lower than the overall median value 
and 3 patients with ΔPA/Aopost-pre lower than the overall 
median ΔPA/Aopost-pre. This could be explained considering 
that only one of our patients had already progressed to 
the late phase of mostly consolidative pulmonary damage, 
during which—as already demonstrated in various types 
of acute and chronic pulmonary interstitial disease (8-10, 
16,17)—pulmonary hypertension severity reaches its peak. 
However, a relatively better correlation with PnE was found 
for ΔPA/Aopost-pre than for ΔPApost-pre. Indeed, ΔPA/Aopost-pre is 
known to be a more robust parameter for the evaluation of 
Figure 6 Category-divided scatter plot of per-patient ΔPApost-pre 
values. A, minimal pneumonia extent; B, mild pneumonia extent; 
C, moderate pneumonia extent; D, severe pneumonia extent. The 
blue horizontal line represents the overall median ΔPApost-pre value. 
Figure 7 Category-divided scatter plot of per-patient ΔPA/Aopost-pre 
values. A, minimal pneumonia extent; B, mild pneumonia extent; C, 
moderate pneumonia extent; D, severe pneumonia extent. The blue 
horizontal line represents the overall median ΔPA/Aopost-pre value. 
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pulmonary hypertension (10,17). 
The overall weakness of these correlations, and especially 
the fact that only the PApost diameter was higher in patients 
who subsequently died than in discharged patients, suggest 
that pulmonary vascular metrics of COVID-19 patients 
and their relation with outcome are also influenced by 
factors other than PnE. Hypotheses to explain such findings 
could involve both a viral-induced autoimmune endothelial 
damage, already associated to other coronaviruses such as 
SARS-CoV-1 in the early 2000s (26), and a large spectrum 
of procoagulant abnormalities, increasingly observed in 
COVID-19 patients. These abnormalities include high 
levels of D-dimer and fibrin degradation products, presence 
of antiphospholipid antibodies, longer prothrombin time 
and activated partial thromboplastin time (15,19-25), 
resulting in pulmonary arterial thrombosis (13,14). Patients 
with a low increase in pulmonary metrics could be less 
affected by endothelial damage and thrombosis, already 
reported in COVID-19 patients with poor prognosis 
(12,19-25,27,28). 
The observation that—among vascular metrics—only 
PA diameter was significantly higher in patients with 
unfavorable outcome than in discharged patients, could 
be related to a precocious manifestation of pulmonary 
arterial thrombosis. Thus, pulmonary vascular metrics 
on unenhanced CT scans could be useful to understand 
patients’ conditions, possibly working as a gate-keeper 
to contrast-enhanced CT, especially in patients with a 
mismatch between PnE and oximeter saturation data. Early 
detection of pulmonary hypertension at admission could 
also guide treatment of COVID-19 patients, triggering 
modifications of anticoagulation therapies from prophylactic 
to therapeutic dosage (21,27,29).
This study has limitations, the main one being the 
limited number of patients. We included all confirmed 
COVID-19 patients with a previous chest CT, performed 
for any reason (except cardiovascular diseases) at any time, 
even those with old previous CTs: this could bias the 
value of comparing previous pulmonary vascular metrics 
with those during infection. Moreover, tachypnoea and 
dyspnea are common in COVID-19 patients and motion 
artifacts during CT examinations could have influenced 
the measurements. Another limitation of our study is the 
manual measurement of great vessels diameters on axial 
scans, which is only a rough approximation for real vessels’ 
size. A more accurate approach would be to measure vessel 
areas on reformatted oblique reconstructions considering 
vessels’ axes, also considering the potential role of automatic 
recognition and measurement, already demonstrated for 
Ao on MRI (30). In addition, three-dimensional vascular 
metrics and flow parameters obtained by MRI or contrast-
enhanced CT could also be considered in future studies. 
In conclusion, COVID-19 patients showed higher 
median PA maximum diameter and median PA/Ao ratio 
compared to values measured on previous chest CTs 
performed for any reason except cardiovascular diseases. 
In this limited cluster of fragile patients, PA maximum 
diameter showed significant difference between patients 
with favorable and unfavorable outcome, a finding deserving 
further investigation as a potential driver of therapy 
decision-making.
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